Sandra Valdivielso Moré

Prof. Sandra Valdivielso Moré

Cardiology, Hospital Del Mar, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LTLaia Carla Belarte Tornero
Laia Carla Belarte Tornero
SMSandra Valdivielso Moré
Sandra Valdivielso Moré
MEMiren Vicente Elcano
Miren Vicente Elcano
EGEduard Sole Gonzalez
Eduard Sole Gonzalez
SBSonia Ruiz Bustillo
Sonia Ruiz Bustillo
NFNuria Farre
Nuria Farre
Background: The prevalence and prognostic value of chronic heart failure (CHF) in the setting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has seldom been studied. The aim of this study was to analyze the prevalence and prognosis of CHF in this setting. Methods: This single-center study included 829 consecutive patients with SARS-CoV-2 infection from February to April 2020. Patients with a previous history of CHF were matched 1:2 for age and sex. We analyze the prognostic value of pre-existing CHF. Prognostic implications of N terminal pro brain natriuretic peptide (NT-proBNP) levels on admission in the CHF cohort were explored. Results: A total of 129 patients (43 CHF and 86 non-CHF) where finally included. All-cause mortality was higher in CHF patients compared to non-CHF patients (51.2% vs. 29.1%, p = 0.014). CHF was independently associated with 30-day mortality (hazard ratio (HR) 2.3, confidence interval (CI) 95%: 1.26–2.4). Patients with CHF and high-sensitivity troponin T < 14 ng/L showed excellent prognosis. An NT-proBNP level > 2598 pg/mL on admission was associated with higher 30-day mortality in patients with CHF. Conclusions: All-cause mortality in CHF patients hospitalized due to SARS-CoV-2 infection was 51.2%. CHF was independently associated with all-cause mortality (HR 2.3, CI 95% 1.26–4.2). NT-proBNP levels could be used for stratification risk purposes to guide medical decisions if larger studies confirm this finding.

Verified
Journal Article
Open access
PDF file
DLDaniele Luiso
Daniele Luiso
MHMarta Herrero-Torrus
Marta Herrero-Torrus
NBNeus Badosa
Neus Badosa
CRCristina Roqueta
Cristina Roqueta
SBSonia Ruiz Bustillo
Sonia Ruiz Bustillo
NFNuria Farre
Nuria Farre
Background: Information about health-related quality of life (HRQoL) in heart failure (HF) in older adults is scarce. Methods: We aimed to describe the HRQoL of the SENECOR study cohort, a single-center, randomized trial comparing the effects of multidisciplinary intervention by a geriatrician and a cardiologist (intervention group) to that of a cardiologist alone (control group) in older patients with a recent HF hospitalization. Results: HRQoL was assessed by the short version of the disease-specific Kansas Cardiomyopathy Questionnaire (KCCQ-12) in 141 patients at baseline and was impaired (KCCQ-12 < 75) in almost half of the cohort. Women comprised 50% of the population, the mean age was 82.2 years, and two-thirds of patients had preserved ejection fraction. Comorbidities were highly prevalent. Patients with impaired HRQoL had a worse NYHA functional class, a lower NT-proBNP, a lower Barthel index, and a higher Clinical Frailty Scale. One-year all-cause mortality was 22.7%, significantly lower in the group with good-to-excellent HRQoL (14.5% vs. 30.6%; hazard ratio 0.28; 95% confidence interval 0.10–0.78; p = 0.014). In the group with better HRQoL, all-cause hospitalization was lower, and there was a trend towards lower HF hospitalization. Conclusions: The KCCQ-12 questionnaire can provide inexpensive prognostic information even in older patients with HF. (Funded by grant Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials number, NCT03555318).

30 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMarta Herrero-Torrus
Marta Herrero-Torrus
NBNeus Badosa
Neus Badosa
CRCristina Roqueta
Cristina Roqueta
SBSonia Ruiz Bustillo
Sonia Ruiz Bustillo
EGEduard Sole Gonzalez
Eduard Sole Gonzalez
NFNuria Farre
Nuria Farre
Background: The prognosis of older patients after a heart failure (HF) hospitalization is poor. Methods: In this randomized trial, we consecutively assigned 150 patients 75 years old or older with a recent heart failure hospitalization to follow-up by a cardiologist (control) or follow-up by a cardiologist and a geriatrician (intervention). The primary outcome was all-cause hospitalization at a one-year follow-up. Results: All-cause hospitalization occurred in 47 of 75 patients (62.7%) in the intervention group and in 58 of 75 patients (77.3%) in the control group (hazard ratio, 0.67; 95% confidence interval, 0.46 to 0.99; p = 0.046). The number of patients with at least one HF hospitalization was similar in both groups (34.7% in the intervention group vs. 40% in the control group, p = 0.5). There were a total of 236 hospitalizations during the study period. The main reasons for hospitalization were heart failure (38.1%) and infection (14.8%). Mortality was 24.7%. Heart failure was the leading cause of mortality (54.1% of all deaths), without differences between groups. Conclusions: A follow-up by a cardiologist and geriatrician in older patients after an HF hospitalization was superior to a cardiologist’s follow-up in reducing all-cause hospitalization in older patients. (Funded by Beca Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials.gov number, NCT03555318).

8 August 2025 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Closed access
SBSonia Ruiz Bustillo
Sonia Ruiz Bustillo
MVMiren Vicente
Miren Vicente
PRPilar Ruiz-Rodriguez
Pilar Ruiz-Rodriguez
ALAna María Linás-Alonso
Ana María Linás-Alonso
SMSandra Valdivielso Moré
Sandra Valdivielso Moré
MCMiguel Cainzos-Achirica
Miguel Cainzos-Achirica
Aims: Guidelines emphasize the importance of quadruple therapy in heart failure with reduced ejection fraction (HFrEF), and of achieving target doses quickly. The aim of the MAR-HF-Titration study was to assess the effectiveness of a nurse-led, telemedicine programme for this purpose. Methods and results: Prospective study including 210 HFrEF patients between September 2021 and December 2023. The 6-month follow-up used a telemedicine programme involving daily telemonitoring of vital signs, weight and symptoms, routine laboratory test monitoring, videoconferences and the use of algorithms for drug titration. Mean age was 70 years, 35% women. Mean left ventricle ejection fraction (LVEF) was 31%, 60% had a non-ischaemic aetiology, and 61% newly diagnosed HF. After the intervention, significant increases were achieved in the use of quadruple therapy at any dose (63 vs. 75%; P = 0.001), at ≥50% of the target doses of each drug (10 vs. 44%, P < 0.001), and at target doses of all drugs (0 vs. 19%, P < 0.001). Median titration time was 45 days for beta-blockers, 65 for MRA, and 69 for ARNI. Older age, chronic kidney disease, hypotension, and higher NTproBNP were associated with lower odds of effective titration. The LVEF increased (31–45%, P < 0.001) and the NTproBNP values were significantly reduced (1960–806 pg/mL, P < 0.001). Increases in the use of prognostic medications were also observed in a sub-analysis restricted to participants aged ≥75 years. Conclusion: Our intensive, nurse-led, telemedicine-based programme attained a fast optimization of prognostic therapies in HFrEF and resulted in significant improvements in parameters with prognostic relevance.

1 April 2021 in REC: CardioClinics
Verified
Journal Article
Closed access
MGMarcos García-Guimaraes
Marcos García-Guimaraes
DMDiana Mojón
Diana Mojón
ACAlicia Calvo
Alicia Calvo
AIAndrea Izquierdo
Andrea Izquierdo
LBLaia Belarte-Tornero
Laia Belarte-Tornero
BVBeatriz Vaquerizo
Beatriz Vaquerizo

17 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SMSandra Valdivielso Moré
Sandra Valdivielso Moré
MEMiren Vicente Elcano
Miren Vicente Elcano
AAAnna García Alonso
Anna García Alonso
SSSergi Pascual Sanchez
Sergi Pascual Sanchez
IHIsabel Galceran Herrera
Isabel Galceran Herrera
NFNuria Farre
Nuria Farre
Background: Despite the frequent coexistence of heart failure (HF) in patients with advanced chronic kidney disease (CKD), it has been understudied, and little is known about its prevalence and prognostic relevance. Methods: A retrospective study of 217 patients with advanced CKD (stages 4 and 5) who did not undergo renal replacement therapy (RRT). The patients were followed up for two years. The primary outcome was all-cause death or the need for RRT. Results: Forty percent of patients had a history of HF. The mean age was 78.2 ± 8.8 years and the mean eGFR was 18.4 ± 5.5 mL/min/1.73 m2. The presence of previous HF identified a subgroup of high-risk patients with a high prevalence of cardiovascular comorbidities and was significantly associated with the composite endpoint of all-cause hospitalization or need for RRT (66.7% vs. 53.1%, HR 95% CI 1.62 (1.04–2.52), p = 0.034). No differences were found in the need for RRT (27.6% vs. 32.2%, p = 0.46). Nineteen patients without HF at baseline developed HF during the follow-up and all-cause death was numerically higher (36.8 vs. 19.8%, p = 0.1). Conclusions: Patients with advanced CKD have a high prevalence of HF. The presence of previous HF identified a high-risk population with a worse prognosis that required close follow-up.